Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07518901 · ClinicalTrials.gov registry record · Phase 4
Nanozymes in Endodontics
A Phase 4 study, sponsored by University of Pennsylvania.
- Not yet
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT07518901: Clinical Trial Phase 4 study, sponsored by University of Pennsylvania.
NCT07518901 is a Phase 4 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 72 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07518901, a Phase 4 study, has not yet begun recruiting, sponsored by University of Pennsylvania.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
The antimicrobial efficacy and healing potential of clinically approved ferumoxytol nanozymes versus the standard 3% NaOCl irrigant will be evaluated in adults undergoing endodontic treatment. Building on prior protocols that demonstrated ferumoxytol nanozymes antimicrobial activity as a root canal irrigant, ferumoxytol solution will be applied topically, assessment of clinical and radiographical findings will determine its potential as a novel disinfection and its long-term outcome.
Interventions
- DRUG Control (Standard treatment)
- DRUG Nanozyme treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-06 |
| Phase | Phase 4 |
What is known before NCT07518901 opens enrollment
NCT07518901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Control (Standard treatment) is the first listed.
NCT07518901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07518901 about?
NCT07518901 is a clinical study titled "Nanozymes in Endodontics". The antimicrobial efficacy and healing potential of clinically approved ferumoxytol nanozymes versus the standard 3% NaOCl irrigant will be evaluated in adults undergoing endodontic treatment. Building on prior protocols that demonstrated ferumoxytol nanozymes antimicrobial activity as a root canal ...
What is the current status of trial NCT07518901?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2026-06. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07518901?
The interventions under investigation include: Control (Standard treatment) (DRUG), Nanozyme treatment (DRUG).
Who is sponsoring clinical trial NCT07518901?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07518901's enrollment target sits among peer trials
72 1035th of 2000 higher than 961 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia